Physician profile
Inder Tandon
NPI 1811276553
$1,574.74
in general payments reported to CMS, 2019-2025
15 companies · $285 in 2025
The $285 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $507 · 2020: $258 · 2021: $228 · 2022: $78.00 · 2023: $82.06 · 2024: $136 · 2025: $285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $502.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $431.42 | 2019-2025 | Ubrelvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $240.27 | 2019-2025 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $226.86 | 2023-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $185.15 | 2019-2024 | Entyvio |
| Janssen Biotech, INC. | $101.81 | 2019-2025 | Tremfya |
| Ironwood Pharmaceuticals, INC | $70.64 | 2020-2021 | |
| Intercept Pharmaceuticals, INC. | $70.38 | 2019-2020 | |
| Vivus LLC | $65.24 | 2022 | |
| Gilead Sciences, INC. | $51.82 | 2019-2020 | |
| Madrigal Pharmaceuticals | $35.82 | 2025 | Rezdiffra |
| Organon LLC | $31.80 | 2023 | Renflexis, Hadlima |
| Erbe USA INC | $18.00 | 2025 | Vio3/Apc3 |
| Boston Scientific Corporation | $17.58 | 2021 | |
| Pfizer INC. | $16.48 | 2024 | |
| Allergan, INC. | $11.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Inder Tandon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.